Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 58 Carcinoma, Hepatocellular 28 Breast Neoplasms 26 Small Cell Lung Carcinoma 20 Lung Neoplasms 20 Triple Negative Breast Neoplasms 18 Urinary Bladder Neoplasms 17 Neoplasms 16 Carcinoma, Transitional Cell 16 Neoplasm Metastasis 15 Melanoma 15 Colorectal Neoplasms 15 Uterine Cervical Neoplasms 11 Carcinoma, Renal Cell 10 Stomach Neoplasms 7 Recurrence 7 Head and Neck Neoplasms 7 Prostatic Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Sarcoma 5 Mesothelioma, Malignant 5 Liver Neoplasms 5 Carcinoma, Squamous Cell 5 Ovarian Neoplasms 4 Esophageal Neoplasms 4 Carcinoma, Merkel Cell 4 Biliary Tract Neoplasms 4 Urethral Neoplasms 3 Ureteral Neoplasms 3 Thoracic Neoplasms 3

Interventions

nimotuzumab 1 lenvatinib 1 atezolizumab 1 Sorafenib 1 Radiotherapy 1 Radiosurgery 1 Immune Checkpoint Inhibitors 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × HCC × atezolizumab × Clear all

NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡